Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Total Stockholders Equity : ¥4,805 Mil (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Hunan Er-Kang Pharmaceutical Co Total Stockholders Equity?

Hunan Er-Kang Pharmaceutical Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ¥4,805 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Hunan Er-Kang Pharmaceutical Co's Book Value per Share for the quarter that ended in Mar. 2024 was ¥2.33. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Hunan Er-Kang Pharmaceutical Co's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.07.

Hunan Er-Kang Pharmaceutical Co Total Stockholders Equity Historical Data

The historical data trend for Hunan Er-Kang Pharmaceutical Co's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hunan Er-Kang Pharmaceutical Co Total Stockholders Equity Chart

Hunan Er-Kang Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

5,818.99

5,811.04

4,851.21

5,051.03

4,836.05

Hunan Er-Kang Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															5,054.29	5,104.55	5,082.27	4,836.05	4,805.08

Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Hunan Er-Kang Pharmaceutical Co's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(4805.082	-	0)	/	2062.6
	=	2.33

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Hunan Er-Kang Pharmaceutical Co's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(353.208	+	0.612)	/	4805.082
	=	0.07

Hunan Er-Kang Pharmaceutical Co Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Hunan Er-Kang Pharmaceutical Co's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hunan Er-Kang Pharmaceutical Co Ltd (SZSE:300267) » Definitions » Total Stockholders Equity

Traded in Other Exchanges

N/A

Address

Kangping Road 167, National Economic and Technological Development Zone, Liuyang Changsha, Hunan, CHN, 410331

Website

http://www.hnerkang.com

Hunan Er-Kang Pharmaceutical Co Ltd develops, produces and sells pharmaceutical products in China. The company's main products include pharmaceutical excipients and antibiotics. It offers pharmaceutical excipients, APIs and finished drug products. The pharmaceutical excipients include products such as glycerol, ethanol pharmaceutically, acceptable propylene glycol, sodium hydroxide, and pharmaceutically acceptable sugar. The company's finished drugs primarily include sulbenicillin sodium for injection and compound liquorice tablets. Its APIs include glycerin, dilute hydrochloric acid, dihydroxypropyl theophylline, sulbenicillin sodium, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. Geographically, all the activities are carried out through China.

Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Headlines

No Headlines